The Filing Desk

4D Molecular Therapeutics

FDMT · Nasdaq · Health Care · Financials, fiscal 2019 to 2025

FDMT · Last close · November 13, 2026
$12.23
Value 4D Molecular Therapeutics yourself

4D Molecular Therapeutics' revenue rose 230194.6% to $85 million in fiscal 2025. Its operating margin was −187.2%, up from −507,678.4% a year earlier. Free cash flow was −$110 million. The diluted share count rose 7.4%.

4D Molecular Therapeutics, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 18, 2026 · 0001193125-26-114075 Updated
Revenue
$85M
230194.6%
Operating margin
−187.2%
507491.1 pts
Net income
−$140M
 
Free cash flow
−$110M
 
Return on equity
−27.6%
11.7 pts
Market cap
$884M
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What 4D Molecular Therapeutics does

4D Molecular Therapeutics is a late-stage biotechnology company developing gene therapies, which are medicines that deliver genetic instructions into a patient's cells. It builds its own delivery vehicles, called vectors, and has programs in two areas, eye disease and lung disease.

Its lead candidate, 4D-150, uses the company's R100 vector to deliver instructions for making a drug that blocks a growth signal called VEGF. It is in Phase 3 testing for wet age-related macular degeneration, an eye disease that damages central vision, and is preparing for Phase 3 in diabetic macular edema. The goal is a lasting treatment given in the doctor's office that reduces how often patients need treatment. Another candidate, 4D-710, is in Phase 2 for cystic fibrosis.

The company has no products approved for sale and has never earned revenue from product sales. It plans to move 4D-150 through Phase 3 and, if that works, to sell it, while moving its early programs to first human proof of concept.

Its biggest risks, as it describes them

  • It has no approved products and a limited operating history, with its lead program in late-stage development.
  • It has lost money every year and will need substantial additional capital.
  • Its candidates could cause side effects that halt development or block approval.
  • Few patients have the diseases it studies, which may make trials harder to finish or to prove.
  • Public worry or regulatory scrutiny of genetic medicines could slow its progress.
From 4D Molecular Therapeutics's annual report on Form 10-K, filed March 18, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

4D Molecular Therapeutics lost money in fiscal 2025: a net loss of $140 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments248214288425514
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—————
Current ratio15.7x14.0x15.7x14.9x9.4x
Quick ratio15.7x14.0x15.7x14.9x9.4x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project 4D Molecular Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of 4D Molecular Therapeutics reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40183.2%−374,075.5%230,066.0%
Altman Z''9.229.926.96
Accruals ratio−8.3%−5.8%−5.5%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailFailPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio rosePassFailFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsPassFailPass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put 4D Molecular Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
4D Molecular TherapeuticsFY25230,194.6%−187.2%−128.7%———
CytokineticsFY25376.6%−695.4%−607.5%———Compare
MeiraGTxFY25144.6%−130.2%−61.7%——3Compare
CytomX TherapeuticsFY25−44.8%−29.4%−99.5%———Compare
Recursion PharmaceuticalsFY2526.9%−867.9%−506.5%−117.2%—4Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

7 years of figures

Fiscal yearFY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue71418321085
Revenue growth—94.8%32.5%−82.7%562.3%−99.8%230,194.6%
Gross profit———————
Research and development3953618097141196
Operating income−51−57−71−110−113−188−160
Net income−49−57−71−108−101−161−140
Diluted EPS (US$)−9.59−8.82−2.57−3.32−2.58−2.98−2.42
Diluted shares (millions)562832395458
Cash flow
Cash from operations−37−51−69−87−76−135−109
Capital expenditure31912340
Free cash flow−40−52−78−98−79−138−110
Dividends paid0000000
Share buybacks0000000
Acquisitions0000000
Stock-based compensation451417202622
Balance sheet at fiscal year end
Cash and short-term investments50277248214288425514
Debt incl. finance leases———————
Total assets58288354262340560567
Total liabilities28323430325061
Shareholders' equity−73256319231308511506
Margins and ratios
Gross margin———————
Operating margin−726.6%−416.3%−395.5%−3,516.5%−544.6%−507,678.4%−187.2%
Net margin−705.8%−416.5%−395.4%−3,435.4%−486.6%−434,778.4%−164.4%
Free cash flow margin−571.3%−381.4%−433.8%−3,139.1%−379.1%−373,975.7%−128.7%
Rule of 40 (growth + FCF margin)—−286.5%−401.3%−3,221.7%183.2%−374,075.5%230,066.0%
Return on capital———————
Return on equity—−61.8%−24.8%−39.1%−37.4%−39.3%−27.6%
Return on assets—−32.7%−22.2%−34.9%−33.5%−35.7%−24.9%
Net debt to EBITDA———————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: 4D Molecular Therapeutics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with 4D Molecular Therapeutics.